XNYS · Healthcare · Medical Instruments & Supplies
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Q1 2026 | 0.05 | 0.08 | +60.00% | $1.24B | ✅ Beat | +2.23% | +4.30% | +2.02% |
| 2026-02-18 | Q4 2025 | 0.35 | 0.32 | -8.57% | $1.41B | ❌ Miss | -5.25% | +5.26% | -11.04% |
| 2025-10-29 |
| Q3 2025 |
| 0.16 |
| 0.18 |
| +12.50% |
| $1.28B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-30 | Q2 2025 | 0.07 | 0.07 | +0.00% | $1.28B | ➖ Inline | +2.32% | +2.92% | +6.71% |
| 2025-04-30 | Q1 2025 | 0.02 | -0.07 | -450.00% | $1.14B | ❌ Miss | +0.26% | -1.38% | -0.78% |
| 2025-02-19 | Q4 2024 | 0.24 | 0.25 | +4.17% | $1.28B | ✅ Beat | -2.52% | -2.70% | -4.54% |
| 2024-10-30 | Q3 2024 | 0.22 | 0.17 | -22.73% | $1.20B | ❌ Miss | -0.78% | -2.98% | -3.03% |
| 2024-07-31 | Q2 2024 | 0.17 | 0.13 | -23.53% | $1.22B | ❌ Miss | -2.09% | -11.21% | -4.59% |
Showing last 8 quarters.